Prevention of Bone Loss in Type I Diabetic Osteoporosis Mice by  Hypoxia Mimicking Agent Deferoxamine

Objective: The overall objective of this study was to investigate the effects of catalpol on bone remodeling of diabetic osteoporosis by regulating osteoblast differentiation and migration.Method: Using a murine model of diabetic osteoporosis, to detect the protective effects of catalpol on bone loss, architectural deterioration of trabecular bone and bone metabolism biomarkers were tested. A model of MC3T3-E1 cells was established by treatment with high glucose; the regulatory role of catalpol in the differentiation and migration was tested by Western blot, ALP staining, and Alizarin Red staining.Results: Catalpol treatment markedly ameliorated trabecular bone deterioration by reducing degenerative changes of the trabecular structure by improving the bone formation marker levels of ALP, osteopontin, type I collagen, and osteocalcin, as well as the level of OPG/RANKL. Catalpol enhanced cell motility and scattering following gap formation of MC3T3-E1 cells.Conclusion: The results indicated that catalpol exhibits a protective effect against diabetic osteoporosis by regulating the differentiation and migration of osteoblast.

Download Full-text

Vitamin D and HRT: No benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study

Osteoporosis International ◽

10.1007/bf01623687 ◽

1997 ◽

Vol 7 (2) ◽

pp. 126-132 ◽

Cited By ~ 24

Author(s):

M. Komulainen ◽

M. T. Tuppurainen ◽

H. Kröger ◽

A. M. Heikkinen ◽

E. Puntila ◽

...

Keyword(s):

Vitamin D ◽

Bone Loss ◽

Postmenopausal Women ◽

Controlled Study ◽

Early Postmenopausal Women ◽

Prevention Of Bone Loss

Download Full-text

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis

Journal of Hepatology ◽

10.1016/s0168-8278(97)80048-7 ◽

1997 ◽

Vol 26 (2) ◽

pp. 325-330 ◽

Cited By ~ 84

Author(s):

Frank H.J. Wolfhagen ◽

Henk R. van Buuren ◽

Janny W. den Ouden ◽

Wim C.J. Hop ◽

Johannes P.T.M. van Leeuwen ◽

...

Keyword(s):

Primary Biliary Cirrhosis ◽

Bone Loss ◽

Biliary Cirrhosis ◽

Cyclical Etidronate ◽

Prevention Of Bone Loss

Download Full-text

Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

Osteoporosis International ◽

10.1007/s00198-012-1930-0 ◽

2012 ◽

Vol 23 (11) ◽

pp. 2577-2577 ◽

Cited By ~ 1

Author(s):

R. Rizzoli ◽

◽

J. J. Body ◽

A. DeCensi ◽

J. Y. Reginster ◽

...

Keyword(s):

Breast Cancer ◽

Bone Loss ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Position Paper ◽

Prevention Of Bone Loss

Download Full-text

Radix Dipsaci extract protects against Rosiglitazone induced bone loss

International Journal of Current Research in Chemistry and Pharmaceutical Sciences ◽

10.22192/ijcrcps.2021.08.09.003 ◽

2021 ◽

Vol 8 (9) ◽

pp. 15-21

Author(s):

Khalid A Asseri ◽

◽

Yahya I Asiri ◽

Ali Alqahtani ◽

Krishnaraju Venkatesan ◽

...

Keyword(s):

Oxidative Stress ◽

Bone Loss ◽

Bone Fractures ◽

Scientific Evidence ◽

Streptozotocin Diabetes ◽

Diabetic Control ◽

Albino Rats ◽

Protective Effects ◽

Diabetes Group ◽

Diabetic Osteoporosis

The dried root of Dipsacus asperoides is known as Radix Dipsaci extract(RDE). It's a kidney-toning herbal medication with a lengthy track record of safe usage in the treatment of bone fractures and joint disorders. The drug rosiglitazone (RSG) causes an imbalance in bone remodelling, which results in increased apoptotic death of osteogenic cells and decreased bone production. The goal of this study was to investigate the effects of RDE on RSGinduced bone loss in diabetic rats in a systematic way. Five groups of six Wistar albino rats were studied: control (vehicle therapy), Streptozotocin (diabetes) group, RDE group, Rosiglitazone, and Rosiglitazone +RDE group. Insulin, oxidative stress, and bone turnover markers in the blood were all detected using ELISA tests. When compared to diabetic control rats, RDE therapy significantly raised insulin and osteocalcin levels. RDE may be able to prevent diabetic osteoporosis by boosting osteogenesis and lowering oxidative stress in the bone.These findings support the use of RDE as a bone loss inhibiting in diabetics. Well-designed clinical trials are likely to yield further scientific evidence on its bone-protective effects and safety. Keywords: Radix Dipsaci, Diabetic osteoporosis, Rosiglitazone.

Download Full-text